A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201
Clinical trial NCT00831649 · TERMINATED
Trial details
- NCT number
- NCT00831649
- Sponsor
- Biogen
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2004-09-01
- Primary completion
- 2005-02-01
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.